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Abstract
Microvascular hyperpermeability that occurs at the level of the blood-brain barrier (BBB)
often leads to vasogenic brain edema and elevated intracranial pressure following traumatic
brain injury (TBI). At a cellular level, tight junction proteins (TJPs) between neighboring
endothelial cells maintain the integrity of the BBB via TJ associated proteins particularly,
zonula occludens-1 (ZO-1) that binds to the transmembrane TJPs and actin cytoskeleton
intracellularly. The pro-inflammatory cytokine, interleukin-1β (IL-1β) as well as the proteo-
lytic enzymes, matrix metalloproteinase-9 (MMP-9) are key mediators of trauma-associated
brain edema. Recent studies indicate that melatonin a pineal hormone directly binds to
MMP-9 and also might act as its endogenous inhibitor. We hypothesized that melatonin
treatment will provide protection against TBI-induced BBB hyperpermeability via MMP-9
inhibition. Rat brain microvascular endothelial cells grown as monolayers were used as an
in vitromodel of the BBB and a mouse model of TBI using a controlled cortical impactor was
used for all in vivo studies. IL-1β (10 ng/mL; 2 hours)-induced endothelial monolayer hyper-
permeability was significantly attenuated by melatonin (10 μg/mL; 1 hour), GM6001 (broad
spectrum MMP inhibitor; 10 μM; 1 hour), MMP-9 inhibitor-1 (MMP-9 specific inhibitor; 5 nM;
1 hour) or MMP-9 siRNA transfection (48 hours) in vitro. Melatonin and MMP-9 inhibitor-1
pretreatment attenuated IL-1β-induced MMP-9 activity, loss of ZO-1 junctional integrity and
f-actin stress fiber formation. IL-1β treatment neither affected ZO-1 protein or mRNA
expression or cell viability. Acute melatonin treatment attenuated BBB hyperpermeability in
a mouse controlled cortical impact model of TBI in vivo. In conclusion, one of the protective
effects of melatonin against BBB hyperpermeability occurs due to enhanced BBB integrity
via MMP-9 inhibition. In addition, acute melatonin treatment provides protection against
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Introduction
Microvascular hyperpermeability is the abnormal extravasation of plasma proteins and fluid into
extravascular space and often results in vasogenic edema. Hyperpermeability in the brain occurs
at the level of the blood-brain barrier (BBB). The BBB is a semipermeable membrane that sepa-
rates the systemic circulation from the brain parenchyma and its optimal functioning is crucial
for the maintenance of brain homeostasis. The key structural and functional elements that main-
tain the integrity of the BBB are the tight junctions between the neighboring endothelial cells [1].
Tight junctions primarily consists of transmembrane (occludin, claudins, junctional adhesion
molecules etc.) and membrane-bound (zonula occludens [ZO]) tight junction proteins.
Zonula occludens-1 (ZO-1) acts as a scaffolding molecule mediating the link between the
transmembrane tight junctions and the actin cytoskeleton [1]. It plays an important role in
maintaining the important properties of the BBB including resistance and permeability [1].
Alterations in BBB integrity leading to hyperpermeability and vasogenic edema often occur fol-
lowing inflammation [2,3].
A variety of pro-inflammatory molecules are activated following various vascular disorders
associated with traumatic brain injury (TBI), ischemia, cerebral infections, stroke, brain dis-
eases, etc [4,5]; leading to various ill-pathologies like microvascular leakage, brain edema, neu-
ronal injury and death [3,6]. Interleukin-1 beta (IL-1β) plays a central role in mediating the
process of neuroinflammation in a variety of pathologies [7]. It is a well-studied pro-inflamma-
tory cytokine known to induce hyperpermeability in brain endothelial cell monolayers
[3,5,8,9]. It also plays an important role in TBI pathophysiology [5].
Matrix metalloproteinases (MMPs) are calcium-dependent zinc-containing proteases that
play important roles in the pathophysiology of a variety of diseases. Matrix metalloproteinase-
9 (MMP-9) activity and IL-1β levels increase in brain following TBI; also, the role of MMP-9 in
BBB tight junction dysfunction is known [10–12]. Studies done byWu et al (2010) in intracere-
bral hemorrhagic (ICH) models suggest that IL-1βmay be a key mediator of MMP-9 activation
and subsequent disruption of ZO-1 [13]. So far, there are no evidences that confirm the direct
contribution of MMP-9 in mediating IL-1β-induced BBB hyperpermeability, although other
pro-inflammatory molecules like tumor necrosis factor-alpha (TNF-α) are shown to induce
MMP-9 activity and endothelial hyperpermeability [14]. Hence, we hypothesized that IL-1β
treatment-induced BBB hyperpermeability may occur via MMP-9-mediated mechanisms.
Our studies further explored the role of melatonin as a potential MMP-9 inhibitor apart
from being a pineal hormone with anti-inflammatory and anti-oxidant properties, based on
the recent studies done by Rudra et al (2013), which indicate that melatonin inhibits MMP-9
by binding to its active catalytic site [15]. Recent studies from our laboratory demonstrate the
anti-MMP-9 properties of melatonin following burn injury-induced endothelial hyperperme-
ability [16]. However, the role of melatonin in regulating IL-1β-induced BBB hyperpermeabil-
ity, particularly the involvement of the BBB tight junctions or its effect on TBI-induced BBB
hyperpermeability in a mouse model of controlled cortical impact is not known. This study
aims to address the following questions:
Effect of acute IL-1β on BBB endothelial cell hyperpermeability in vitro.
• Comparative effects of melatonin and MMP-9 inhibitors on IL-1β-induced BBB hyperper-
meability, loss of tight junctional integrity, changes in actin cytoskeletal assembly, MMP-9
activity, cell viability and ZO-1 protein/gene expression in vitro.
Melatonin Protects the Blood-Brain Barrier
PLOS ONE | DOI:10.1371/journal.pone.0154427 May 6, 2016 2 / 18
metalloproteinase-9; PBS, phosphate buffered saline;
RBMEC, rat brain microvascular endothelial cells; TJ,
Tight Junctions; TBI, Traumatic Brain Injury.
• Protective effects of melatonin against BBB breakdown induced by TBI in a mouse controlled
cortical impact model of TBI in vivo.
Materials and Methods
Materials
Rat Brain Microvascular Endothelial Cells (RBMECs) and RBMECMedium were obtained
from Cell Applications Inc. (San Diego, CA). SensoLyte1 520 MMP-9 fluorometric Assay Kit
was purchased from Anaspec Inc. (San Jose, CA). Transwell1-well plates were obtained from
Corning Costar (New York, USA). Nunc Lab Tek II- CC, 8-well glass chamber slides, Interleu-
kin-1β human, melatonin, fibronectin from bovine plasma, β-actin, albumin from bovine
serum, Evans blue, trichloroacetic acid and fluorescein isothiocyanate-dextran-10 kDa were
purchased from Sigma Aldrich (St. Louis, MO). Rabbit anti ZO-1 (Cat # 617300), mouse anti
ZO-1 (Cat # 339100), 0.25% Trypsin (1X), Opti-MEM (1X)/reduced serum medium, Dulbec-
co's modified Eagle’s medium (DMEM; with high glucose, HEPES, no phenol red (1X)),
NuPAGE Novex1 10% Bis-Tris protein gels, NuPAGE1MOPS SDS Running Buffer,
NuPAGE1 Transfer Buffer, HyClone Dulbecco's phosphate buffered saline (PBS, without cal-
cium, magnesium, or phenol red), TRIzol1 Reagent, SuperScript1 IV First-Strand Synthesis
System, Halt1 Protease Inhibitor Cocktail (100X), Pierce™ ECLWestern Blotting substrate
and rhodamine phalloidin were purchased from Thermo Fisher Scientific (Carlsbad, CA).
Anti-MMP-9 antibody (cat # ab-3) was obtained from EMDMillipore (Billerica, MA). Goat
anti-mouse IgG-HRP and donkey anti-rabbit IgG-FITC secondary antibodies were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). EZViable™ Calcein AM Cell Viability
fluorometric assay kit was bought from Biovision (Milpitas, CA). We also purchased Vector
VECTASHIELD1Mounting Media with DAPI from Vector Laboratories (Burlingame, CA).
Pierce™ BCA Protein Assay Kit and RT2 qPCR Primer Assay for Mouse GAPDH were pur-
chased from Qiagen (Valencia, CA). GM6001 (also called as Ilomastat or Galardin) and MMP-
9 inhibitor 1 were purchased from Calbiochem (Billerica, MA). Cell Lysis Buffer (10X) was
bought from Cell Signaling Technology, Inc. (Danvers, MA). Primers were purchased from
Thermo Fisher Scientific (Carlsbad, CA). MMP-9 siRNA and control siRNA (ON-TARGET-
plus siRNA) were purchased from Dharmacon, General Electric (Pittsburgh, PA).
Cell culture
Primary cultures of RBMECs derived from the brain of adult Sprague Dawley rats were pur-
chased from the Cell Applications Inc. (San Diego, CA). RBMECs were initially grown on
0.05% fibronectin-coated cell culture dishes, using the RBMEC medium in a cell culture incu-
bator (95% O2, 5% CO2 at 37°C). Endothelial cells were treated with 0.25% trypsin-EDTA for
cell detachment. Detached cells were then grown on fibronectin-coated Transwell1 inserts,
chamber slides or 100 mm dishes for experimental purposes. RBMEC passages 8–10 were cho-
sen for all the experiments.
Animals and surgeries
C57BL/6 mice (25–30 g) were purchased from Charles River Laboratories (Wilmington, MA).
Animals were maintained at the Texas A&MUniversity Health Science Center College of Med-
icine and Baylor Scott and White Health animal facility on a 12:12 hour dark/light cycle, with
free access to food and water. The room temperature was maintained at 25° ± 2°C. Surgical and
experimental procedures used in this study were conducted after approval from the Baylor
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Scott and White Health/Texas A&MUniversity Health Science Center College of Medicine
Institutional Animal Care and Use Committee. The facility is approved by the Association for
Assessment and Accreditation of Laboratory Animal Care International in accordance with the
National Institutes of Health guidelines. The animals were anesthetized with urethane, i.p.
injection (2 mL/kg body weight) and was continuously observed by an investigator till the end
of the study (up to one hour following traumatic brain injury). Our studies show that at this
dose of urethane, animals are under deep anesthesia and has minimized any animal suffering.
One-hour post-injury, animals were transcardially perfused with sterile saline containing hepa-
rin (1000 U/mL) for at least 20 minutes. This was not a survival study and no unexpected ani-
mal death was observed. The details of surgical procedures and the associated studies are
described in detail in various sections below:
Craniotomy Procedure. The head of the animal was shaven and the surgical site on the
surface of the head was cleaned with an alcohol wipe. Lubricating ointment was applied to the
eyes. Midline incision on the scalp helps to remove the skin from top of the skull exposing the
sagittal suture, bregma and lambda. A circular craniotomy window, 3–4 mm in diameter was
made on ipsilateral hemisphere, between lambda and bregma using a microdrill. The resulting
bone flap was removed. Sham animals received only craniotomy surgery, while TBI injury
group received brain injury via controlled cortical impactor following craniotomy procedure.
Controlled cortical impactor and TBI. These studies employ Benchmark™ Stereotaxic
Impactor from Leica, for inflicting TBI in mice. Following craniotomy procedure, the animals
were mounted on the stereotaxic frame. An impactor probe of 3 mm diameter was used to
impact the exposed part of the brain. The depth of the injury was used to determine the severity
of the injury. Settings for mild TBI used in this study are: 2 millimeters depth, 0.5 meters/sec-
ond velocity and 100 milliseconds contact time as described in Chen et al, 2014 [17].
Treatments
Melatonin at a dose of 10 mg/kg was used for the acute drug administration studies. This dose
was chosen based on the studies done in mouse model of TBI [18]. Melatonin was adminis-
tered via the tail vein along with Evans blue injection and allowed to circulate for 30 minutes
prior to TBI.
Brain endothelial monolayer permeability in vitro
RBMECs were grown on fibronectin-coated Transwell1 inserts as monolayers for 72–96
hours and regularly checked for confluency. Monolayers were initially exposed to phenol red
free DMEM for 45 minutes to an hour. DMEM treated cells were then treated with various
concentrations of IL-1β (1–100 ng/mL) for 2 hours (Panel 1A) or IL-1β (10 ng/mL) treatment
at various time points (1–4 hours; Panel 1B). At the end of the treatment, FITC labeled dex-
tran-10 kDa (5 mg/mL; 30 minutes) was applied to the luminal compartment. One hundred
microliters of sample was collected from the abluminal compartment at the end of 30 minutes
and measured fluorometrically at 485/520 nm (Excitation/Emission) using Fluoroskan Ascent™
FL Microplate Fluorometer and Luminometer (Vantaa, Finland). These studies provided infor-
mation on the minimal dose and time exposure of IL-1β to induce BBB endothelial cell
hyperpermeability.
Using the above information, a separate set of experiments were conducted to study the
effect of GM6001 (broad-spectrum MMP inhibitor; 10 μM; 1 hour; Panel 2A), MMP-9 inhibi-
tor 1 (MMP-9 specific inhibitor; 5 nM; 1 hour; Panel 2B) and melatonin (10 μg/mL; 1 hour;
Panel 2C) pretreatment on IL-1β (10 ng/mL; 2 hours) treatment- induced monolayer
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hyperpermeability. At the end of the experiment, FITC-dextran-10 kDa was added to the
donor chamber and fluorescence intensity measurements were performed as described above.
Melatonin dose and time exposure were chosen from the studies done in our lab in burn
trauma models [16]. MMP-9 inhibitor 1 used in these studies is a cell-permeable, potent, selec-
tive and reversible MMP-9 inhibitor with IC50 at 5 nM for MMP-9 inhibition. It inhibits other
MMPs at concentrations higher or lower than 5 nM, hence 5 nM was specifically chosen for
these studies. MMP-9 inhibitor 1 concentration chosen is also supported by the studies done in
our lab to study the effect of TNF-α on BBB hyperpermeability [14]. The dose and exposure
time for GM6001 were obtained from Simao et al, 2012 [19].
Untreated cells served as control. Each experiment was performed once and then repeated
four or six times. Fluorescence intensity values were plotted on the Y-axis and represented as %
control. Data were expressed as mean ± % SEM and statistical differences among groups were
determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test to
determine significant differences between specific groups. A value of p<0.05 was considered
statistically significant.
Monolayer transfection studies
RBMECs were grown on fibronectin-coated Transwell1 inserts for 24 hours and treated with
control siRNA or MMP-9 siRNA at a concentration of 25 nM for 48 hours. Transfection was
performed according to manufacturer’s instructions. Transfected monolayers were then
exposed to IL-1β (10 ng/mL; 2 hours; Fig 3) and permeability was determined based on the
leakage of FITC-dextran-10 kDa (5 mg/mL; 30 minutes) leakage from the luminal to the
abluminal chamber. One hundred microliters of the sample was obtained from the abluminal
chamber and fluorescence intensity was measured at 485/520 nm (Excitation/Emission) using
Fluoroskan Ascent™ FL Microplate Fluorometer and Luminometer.
Untreated or control siRNA transfected cells were used as control. Each experiment was
performed once and then repeated four times. Fluorescence intensity was plotted on the Y-axis
and represented as % control. Data were expressed as mean ± % SEM and statistical differences
among groups were determined by one-way analysis of variance (ANOVA) followed by Bon-
ferroni post hoc test to determine significant differences between specific groups. A value of
p<0.05 was considered statistically significant. In order to determine the efficiency of knock-
down, total proteins from control siRNA or MMP-9 siRNA transfected cells were subjected to
PAGE and immunoblot analysis of MMP-9 protein followed by its quantitative measurement
by using ImageJ software.
Measurement of MMP-9 activity
A SensoLyte1 520 MMP-9 fluorometric Assay Kit was employed to measure the MMP-9
activity in the cells. This kit detects the MMP-9 activity in samples by using a 5- carboxyfluor-
escein Ser—Leu—Gly—Arg—Lys—Ile—Gln—Ile—Gln—Lys(QXL1520)—NH2 (5-FAM/
QXL™ 520 fluorescence resonance energy transfer (FRET) peptide). In intact FRET peptide, the
fluorescence of 5-FAM is quenched by the QXL™ 520. However, on cleavage of the peptide by
MMP-9 fluorescence is recovered and measured at 490/520 nm (Excitation/Emission).
In this procedure, RBMECs were grown in petri dishes until confluency is achieved. Cells
were then pretreated with MMP-9 inhibitor 1 (5 nM; 1 hour; Panel 4A) or melatonin (10 μg/
mL; 1 hour) followed by IL-1β (10 ng/mL; 2 hours; Panel 4B). At the end of the experiment,
cells were washed twice in PBS and exposed to the assay buffer provided in the kit. Cells were
then scraped and the cell lysates were collected. Cell lysates were briefly sonicated and centri-
fuged in order to collect supernatants. Supernatants were used to measure the MMP-9 activity
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in the cells. Equal amounts of proteins were taken in each well and 4-aminophenylmercuric
acetate (APMA) was added to samples and incubated for 2 hours in dark; in order to activate
the pro-MMPs. To the activated samples, MMP-9 substrate, 5-FAM/QXL 520 FRET peptide
was added and incubated for another 30 minutes in dark and read fluorometrically at 490/520
nm (Excitation/Emission).
Untreated cells served as control. Each experiment was performed once and then repeated
four times. MMP-9 activity was expressed as relative fluorescence units (RFU) and plotted on
the Y- axis. Data were expressed as mean ± SEM and statistical differences among groups were
determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test to
determine significant differences between specific groups. A p value of<0.05 was considered
statistically significant.
ZO-1 immunofluorescence and rhodamine phalloidin labeling for f-actin
Zonula occludens-1 junctional localization and f-actin stress fibers were assessed using immu-
nofluorescence and rhodamine phalloidin labeling techniques respectively. RBMECs were
grown on the chamber slides for overnight. Cells were initially exposed to Opti-MEM/reduced
serum medium, followed by pretreatment with MMP-9 inhibitor 1 (5 nM; 1 hour; Panel 5A)
and melatonin (10 μg/mL; 1 hour; Panel 5B) and subsequently with IL-1β (10 ng/mL; 2 hours)
treatment. Cells were then fixed in 4% paraformaldehyde in PBS for 10–15 minutes and per-
meabilized in 0.5% Triton-X 100 in PBS for another 10–15 minutes. Cells were blocked using
2% bovine serum albumin (BSA) in PBS for an hour at room temperature. Cells were then
incubated overnight in anti-rabbit primary antibodies against ZO-1 (#617300; 1:150) in 2%
BSA-PBS, followed by incubation with anti-rabbit IgG-FITC conjugated secondary antibody
for an hour at room temperature. Cells were then washed and mounted using VECTA-
SHEILD1 Antifade Mounting Media with DAPI for nuclear staining.
For rhodamine phalloidin labeling, treatments were performed in the same way as for ZO-1
immunofluorescence study. Following treatments, cells were fixed, permeabilized, and blocked
in 2% BSA-PBS as described earlier. Cells were then labeled with rhodamine phalloidin (1:50)
in 2% BSA-PBS for 20 minutes (Fig 6, Panels A and B). Chamber slides were then washed and
mounted using VECTASHIELD1 Antifade Mounting Media with DAPI for nuclear staining.
Cells were visualized and scanned at a single optical plane with an Olympus Fluoview 300 Con-
focal Microscope (Center Valley, PA), with a PLA PO 60X water immersion objective.
Untreated cells served as control.
Real Time-PCR studies
RBMECs were grown on 100 mm cell culture dishes until 80–90% confluency was reached.
Cells were then pretreated with MMP-9 inhibitor 1 (5 nM; 1 hour) followed by IL-1β (10 ng/
mL; 2 hours) (Fig 7; Panels A and B). Following treatments, cells were washed thrice in PBS
and total RNA was then extracted using TRIzol1 reagent according to the manufacturer’s
instructions. RNA concentration and quality were determined by employing the ratio of absor-
bance at 260/280 nm using Biotek Synergy Hybrid Spectrophotometer (Winooski, VT).
Reverse transcription was performed using the SuperScript1 IV First-Strand Synthesis Sys-
tem. Quantitative real time PCR was performed using the RT2 SYBR Green Fluor qPCR Mas-
termix with the following primer pairs for ZO-1: Forward primer: 50-CCTCTGATCATTCCA
CACAGTC-30, Reverse primer: 50-TAGACATGCGCTCTTCCTCTCT-30, MMP-9: Forward
primer: 5'- GGCTAGGCTCAGAGGTAA-3', Reverse primer: 5'-GACGTTGTGTGAGTTCC
AG-3' and GAPDH: Forward primer: 50-AATGTATCCGTTGTGGATCT-30, Reverse primer:
50-CAAGAAGGTGGTGAAGCAGG-30 were used. Real-time PCR detection was carried out
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using Stratagene Mx3000P qPCR System, Agilent Technologies (La Jolla, CA), using 1 μL of
cDNA for 10 minutes at 95°C, followed by 40 cycles of 15 sec at 95°C for denaturation and 1
min at 60°C for annealing. Relative abundances of target genes were calculated by normalizing
Ct values to endogenous control glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Cells were treated with IL-1β, while untreated cells served as control. Each experiment was
repeated three times. Relative gene expression of ZO-1 was obtained by normalizing the Ct val-
ues to the endogenous control GAPDH for each repeat. Normalized Ct values were expressed
as mean ± SEM. Statistical differences among groups were determined by one-way analysis of
variance (ANOVA) followed by Bonferroni post hoc test to determine significant differences
between specific groups. A p value of<0.05 was considered statistically significant.
Western blot analysis of ZO-1
Western blots were performed to determine the potential changes in ZO-1 protein expression.
Cells were initially exposed to reduced serum medium followed by IL-1β (10 ng/mL; 2 hours)
treatment. At the end of the study, cells were washed twice in ice-cold PBS and incubated in
ice-cold cell lysis buffer (1X) along with protease inhibitor cocktail (1X) for 5 minutes in cell
culture dishes. Cells were then scraped, sonicated and centrifuged at 14,000g for 10 minutes at
4°C. Supernatant was collected from the extracts and protein concentration was determined
using protein assay kit. Equal amounts of total protein (50 μg) were separated by sodium dode-
cyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10% Bis-Tris precast gels at
constant voltage (145 V) for 180 minutes. Proteins were then transferred onto the nitrocellu-
lose membrane at constant voltage (30 V) for overnight and the membranes were blocked
using 5% nonfat dry milk in Tris-Buffered Saline (TBS) with 0.05% Tween-20 and subse-
quently incubated with primary mouse monoclonal anti ZO-1 antibody (1:250 dilution). Mem-
branes were washed thrice in TBS-T and incubated with the goat anti-mouse IgG- HRP
conjugated secondary antibody. After washing, the immunoblots were visualized by ECLWest-
ern Blotting Substrate. Untreated cells served as control. Equal amount of protein sample load-
ing was verified by assessing β-actin protein expression.
Cell viability studies
In order to determine if the changes in permeability was due to the loss of cell viability or not, a
cell viability assay was conducted. An EZViable™ Calcein AM Cell Viability Assay Kit (Fluoro-
metric) was used for quantify the number of viable cells. Calcein AM is a non-fluorescent,
hydrophobic compound that easily penetrates intact and live cells. Hydrolysis of the calcein
AM by intracellular esterase produces a hydrophilic, strongly fluorescent compound that is
retained in the cell cytoplasm, which can be measured at 485/530 nm (Excitation/Emission).
Equal numbers of cells were grown on sterile black 96 well trays. On reaching confluency,
growth media is discarded and cells were washed in PBS and pre-exposed to phenol red-free
medium for 1 hour. Cells were divided into control (untreated) and IL-1β ss(10 ng/mL) treat-
ment groups. Hydrogen peroxide at 100 mM was used as a positive control. Following treat-
ments, cells were then exposed to calcein buffer solution (calcein AM: calcein dilution buffer in
1:500 dilution) and incubated at 37°C for 30 minutes and a fluorometric reading was obtained.
Fluorescence intensity was plotted on the Y-axis and represented as % control. Data were
expressed as mean ± % SEM and statistical differences among groups were determined by one-
way analysis of variance (ANOVA) followed by Bonferroni post hoc test to determine signifi-
cant differences between specific groups. A p value of<0.05 was considered statistically
significant.
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Evans blue leakage studies
Evans blue dye binds to the albumin in the blood enabling us to detect the vascular leakage into
the extravascular tissue following TBI. C57BL/6 mice (25–30 g) were anesthetized with ure-
thane, i.p. injection (2 mL/kg body weight) followed by Evans blue dye, i.v. injection (2% wt/
vol in saline; 4 mL/kg body weight). Melatonin was injected at a concentration of 10 μg per
gram body weight of the animal. A stock of 50μg/μL of 100% alcohol was prepared. Melatonin
from the stock concentration was then diluted in Evans blue, based on the body weight of the
animal. The total alcohol concentration was less than 0.5% of the total blood volume. Evans
blue was allowed to circulate in the animal for 30 minutes prior to performing sham surgery
(only craniotomy) or TBI using controlled cortical impactor. Drugs were given to the animal
along with Evans blue injection and allowed to circulate for 30 minutes as well. Settings for
mild TBI are described in the CCI procedure.
Animals were grouped into Sham (only craniotomy; n = 6), Vehicle + Sham (75% ethanol
injection followed by craniotomy; n = 6), Vehicle + TBI group (75% ethanol followed by mild
TBI; n = 5), and melatonin +TBI group (melatonin [10 μg/gram body weight of the animal]
injection followed by mild TBI; n = 6). The vehicle was combined with Evans Blue when given
and the total alcohol concentration was less than 0.5% of the total blood volume.
One-hour post-TBI, animals were transcardially perfused with sterile saline containing hep-
arin (1000 U/mL) for at least 20 minutes. Brains were extracted and brain cortex was carefully sep-
arated and weighed. Brain cortices were then homogenized in 1 mL of 50% (wt/vol) trichloroacetic
acid (TCA) in saline. Homogenate was then centrifuged at 6,000g for 20 minutes at 4°C. Superna-
tants were extracted and further diluted in 3 parts of ethanol (1:3; 50% TCA: 95% ethanol). Sam-
ples were then quantitated fluorometrically at 620/ 680 nm (Excitation/Emission) using Biotek
Synergy Hybrid H1 spectrophotometer (Winooski, VT). Evans blue concentration in the samples
were evaluated using external standards for Evans blue ranging from 50–1000 ng/mL, prepared in
same solvent (1:3; TCA: 95% ethanol). Evans blue amount in the samples was expressed as ng/
brain cortex ± SEM. Statistical differences among groups were determined by one-way analysis of
variance (ANOVA) followed by Bonferroni post hoc test to determine significant differences
between specific groups. A p value of<0.05 was considered statistically significant.
Statistical Analysis
Data are expressed as the mean ± % SEM for the monolayer permeability, monolayer transfection
and cell viability studies; while mean ± SEM is employed for data obtained fromMMP-9 activity
assay, real time-PCR studies and Evans blue leakage studies. Statistical differences among groups
were determined by one-way ANOVA followed by Bonferroni post hoc test to determine signifi-
cant differences between specific groups. Student’s t-test was employed for comparing the protein
expression data. p<0.05 was considered a statistically significant difference.
Results
IL-1β treatment induces BBB endothelial cell monolayer
hyperpermeability
Endothelial cell monolayers were pretreated with various concentrations of IL-1β ranging from
1–100 ng/mL for a 2-hour period. Results from this study confirmed that IL-1β treatment at 10
ng/mL for 2 hours was found to be the minimal dose to induce monolayer hyperpermeability
(Fig 1; Panel A; p<0.05).
In a separate set of experiments, RBMECs were then treated with IL-1β (10 ng/mL) for vari-
ous time periods ranging from 1 to 4 hours. Result from this study further confirmed that IL-
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1β treatment (10 ng/mL; 2 hours) was the minimal dose to induce RBMEC monolayer hyper-
permeability (Fig 1; Panel B; p<0.05). Hence, IL-1β treatment at 10 ng/mL dose for a 2-hour
period was used to induce monolayer hyperpermeability in the following experiments.
MMP-9 specific inhibition attenuates IL-1β-induced BBB endothelial cell
hyperpermeability
Initial preliminary studies to confirm the involvement of MMPs in mediating IL-1β- induced
monolayer hyperpermeability; GM6001 (broad-spectrum MMP inhibitor) was used. Endothe-
lial cell monolayers were pretreated with GM6001 (Fig 2; Panel A; 10 μM; 1 hour) followed by
IL-1β (10 ng /mL; 2 hours).
To study the effect of MMP-9 specific inhibition, MMP-9 inhibitor 1 and melatonin were
employed. IL-1β (10 ng/mL; 2 hours) treatment-induced monolayer hyperpermeability was
significantly attenuated on pretreatment with MMP-9 inhibitor 1 (Fig 2; Panel B; 5 nM; 1
hour) and melatonin (Fig 2; Panel C; 10 μg/mL; 1 hour). Permeability was assessed by mono-
layer permeability assays as described earlier.
MMP-9 knockdown attenuates IL-1β-induced endothelial cell
hyperpermeability
Significant contribution of MMP-9 in attenuating IL-1β-induced endothelial cell hyperperme-
ability is further supported by siRNA transfection studies. IL-1β (10 ng/mL; 2 hours) treatment
to MMP-9 knockdown (25 nM; 48 hours) cells significantly reduced IL-1β treatment-induced
monolayer hyperpermeability (Fig 3). siRNA treated groups were compared to the control
siRNA group, while the IL-1β alone treated group was compared to the control group.
Immunoblot analysis of MMP-9 protein following transfection of the cells with control
siRNA or MMP-9 siRNA showed a 37% decrease in MMP-9 levels. This decrease was statisti-
cally insignificant (Student’s t-test; S1 Fig).
Fig 1. IL-1β treatment induces dose and time dependent increase in monolayer hyperpermeability. In Panel A, IL-1β treatment at doses 10, 50
and 100 ng/mL for 2 hours are shown to significantly increase BBB permeability compared to the control group (n = 4; p<0.05). Panel B indicates
significant increase in IL-1β induced BBB permeability at 2, 3 and 4 hours compared to the control (n = 4; p<0.05). Monolayer permeability is expressed
as a percentage control of FITC-dextran-10 kDa fluorescent intensity, plotted on the Y-axis. Data are expressed as mean ±%SEM. ‘*a’ indicates
significant increase compared to the control group.
doi:10.1371/journal.pone.0154427.g001
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IL-1β treatment-induced MMP-9 activity is attenuated by pretreatment
with MMP-9 inhibitor 1 and melatonin
IL-1β treatment significantly increased MMP-9 activity in RBMECs, while pretreatment with
MMP-9 inhibitor 1 (5 nM; 1 hour) or melatonin (10 μg/mL; 1 hour) significantly attenuated IL-1β
(10 ng/mL; 2 hours) treatment-inducedMMP-9 activity (Fig 4; Panels A and B). MMP-9 activity
measurements were performed as described in the methods section. MMP-9 inhibitor 1 was used
as a pharmacological inhibitor of MMP-9; however, anti- MMP-9 properties of melatonin are still
not as well-established. Our studies support the role of melatonin as a potential MMP-9 inhibitor.
Fig 2. GM6001, MMP-9 inhibitor 1 andmelatonin pretreatment attenuates IL-1β treatment-inducedmonolayer hyperpermeability. Panel A
indicates the effect of GM6001 (broad-spectrumMMP inhibitor; n = 4); while Panels B and C employ MMP-9 specific inhibitors: MMP-9 inhibitor 1
(n = 4) and melatonin (n = 6) pretreatment on IL-1β (10 ng/mL; 2 hours)—induced monolayer hyperpermeability. Monolayer permeability is
expressed as a percentage control of FITC-dextran-10 kDa fluorescence intensity, plotted on the Y-axis. Data are expressed as mean ±%SEM.
‘*a’ indicates significant increase compared to control group; ‘*b’ indicates significant decrease compared to the IL-1β treated group. p<0.05 was
considered statistically significant.
doi:10.1371/journal.pone.0154427.g002
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Melatonin and MMP-9 inhibitor 1 provides protection against IL-1β
treatment- induced loss of ZO-1 junctional integrity
Cells were processed for immunofluorescence localization of tight junction protein, ZO-1. IL-1β
(10 ng/mL; 2 hours) treatment-induced ZO-1 junctional discontinuity (white arrows; Panel 5A and
B) compared to the control cells (Fig 5). Pretreatment with MMP-9 inhibitor 1 (5 nM; 1 hour) and
melatonin (10 μg/mL; 1 hour) decreased IL-1β treatment- induced ZO-1 junction integrity (Fig 5).
Fig 4. MMP-9 inhibitor 1 andmelatonin pretreatment attenuates IL-1β treatment- induced MMP-9 activity.MMP-9 inhibitor 1 (n = 4)
and melatonin (n = 5) pretreatment attenuated IL-1β treatment-induced MMP-9 activity in RBMECs. MMP-9 activity is expressed as relative
fluorescence units (RFU), plotted on the Y-axis. Data are expressed as mean ± SEM. ‘*a’ indicates significant increase compared to the
control group; ‘*b’ indicates significant decrease compared to the IL-1β (10 ng/mL; 2 hours) treatment group. p<0.05 was considered
statistically significant.
doi:10.1371/journal.pone.0154427.g004
Fig 3. Knockdown of MMP-9 by siRNA attenuates IL-1β treatment-inducedmonolayer hyperpermeability.
Monolayer permeability is expressed as percentage flux of FITC-dextran-10 kDa fluorescence intensity, plotted
on the Y-axis. Data are expressed asmean ±%SEM. ‘*a’ indicates significant increase compared to the control
group; ‘*b’ indicates significant decrease compared to the IL-1β (10 ng/mL; 2 hours) treatment group. siRNA
transfected groups were compared to control siRNA transfected group (n = 4; p<0.05).
doi:10.1371/journal.pone.0154427.g003
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Untreated cells served as control. These studies support that IL-1β treatment-induced monolayer
hyperpermeability occurs via ZO-1 junctional disruption and possibly by ZO-1 redistribution.
Melatonin and MMP-9 inhibitor 1 provides protection against IL-1β
treatment- induced f-actin stress fiber formation
For assessing the cytoskeletal assembly, rhodamine phalloidin labeling technique was per-
formed. Untreated cells served as control. IL-1β treatment-induced f-actin stress fiber forma-
tion (white arrows; Fig 6; Panels A and B) was reduced on pretreatment with MMP-9 inhibitor
1 and melatonin.
IL-1β treatment neither induces ZO-1 mRNA expression nor alters ZO-1
protein expression
IL-1β treatment (10 ng/mL; 2 hours) did not alter ZO-1 or MMP-9 mRNA expression by
RT-PCR studies (Fig 7; Panels A and B). IL-1β treatment (10 ng/mL; 2 hours) did not the alter
ZO-1 protein expression (Fig 7; Panel C).
IL-1β treatment does not induce cell death in endothelial cells
IL-1β treatment at 10 ng/mL for 2 hours did not cause any significant change in cell viability
(Fig 8). Hydrogen peroxide at 100 mM concentration for 2 hours was used as a positive control.
Fig 5. MMP-9 inhibitor 1 andmelatonin pretreatment protects against IL-1β treatment-induced loss of ZO-1 junctional integrity. IL-1β
(10 ng/mL; 2 hours) treatment-induced ZO-1 junctional disruption (white arrows) was decreased on pretreatment with MMP-9 inhibitor 1 (n = 4)
and melatonin (n = 4).
doi:10.1371/journal.pone.0154427.g005
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Hydrogen peroxide significantly attenuated cell viability compared to untreated control group
(p<0.05).
Melatonin pretreatment attenuates TBI-induced BBB hyperpermeability
Mice subjected to TBI demonstrated significant increase in Evans blue leakage compared to the
sham animals. Evans blue extravasation was performed using ipsilateral brain cortices. Pre-
treatment with melatonin attenuated mild TBI-induced Evans blue leakage into the brain tissue
(Fig 9; Panels A and B). Evans blue leakage was assessed fluorometrically at 620/680 nm (Exci-
tation/Emission). This study suggests that melatonin can be used as a potential therapeutic
agent in attenuating BBB hyperpermeability that occurs following TBI.
Discussion
The results from this study demonstrate that melatonin has protective effects against IL-1β-
induced BBB dysfunction and hyperpermeability in vitro via MMP-9 inhibition and by main-
taining tight junctional and cytoskeletal integrity. It also effectively decreases acute BBB hyper-
permeability in a mouse controlled cortical impact model of traumatic brain injury in vivo.
Furthermore, the results show that IL-1β-induced acute barrier dysfunctions are not due to
alterations in endothelial cell viability or a decrease in the content or expression of the key tight
junction associated protein ZO-1.
Fig 6. MMP-9 inhibitor 1 andmelatonin pretreatment reduces IL-1β treatment- induced f-actin stress fiber formation. IL-1β (10 ng/mL; 2
hours) treatment-induced f-actin stress fiber formation (white arrows) was decreased by pretreatment with MMP-9 inhibitor 1 (n = 4) and
melatonin (n = 4).
doi:10.1371/journal.pone.0154427.g006
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Matrix metalloproteinases (MMPs) are zinc and calcium proteases that play several roles in
vascular physiology and pathophysiology [16,20,21]. Matrix metalloproteinase-9 levels are
found to increase significantly in the cerebrospinal fluid (CSF) samples of the traumatic brain
injury patients [11]. Identification of MMP-9 in the CSF may indicate their role in BBB disrup-
tion, which is supported by its ability to degrade various tight junction proteins such as clau-
din-5, occludin, and zonula occludens (ZO-1) in cultured brain endothelial cells [12].
Fig 7. IL-1β treatment does not induce ZO-1 mRNA or protein expression. IL-1β (10 ng/mL; 2 hours) treatment neither induces ZO-
1/MMP-9 mRNA expression (n = 3) nor alter ZO-1 protein expression (n = 4). RT-PCR data plotted on the Y-axis are expressed as
relative expression of ZO-1 normalized to GAPDH. Data are represented as mean ± SEM.
doi:10.1371/journal.pone.0154427.g007
Fig 8. IL-1β treatment does not induce cell death. IL-1β (10 ng/mL; 2 hours) treatment had no effect on cell
viability (n = 5). Hydrogen peroxide (used as a positive control) treatment decreases cell viability significantly
(p<0.05). Data are expressed as mean ±%SEM. ‘*’ indicates statistical significance. ‘*a’ indicates significant
decrease compared to the control group.
doi:10.1371/journal.pone.0154427.g008
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Although studies done in intracerebral hemorrhagic (ICH) models suggest that IL-1βmay
induce MMP-9 activation and subsequent ZO-1 disruption [13], no elaborate studies have
been done to imply its significance in regulating BBB dysfunction and hyperpermeability. Our
studies further employ various MMP inhibitors like GM6001, MMP-9 inhibitor 1 and melato-
nin, in order to study the effect of MMP-9 inhibition on IL-1β-induced BBB dysfunction and
hyperpermeability.
Interleukin-1β upregulation is also observed following experimental brain injuries [13,22]
and it has been attributed to several of the adverse consequences of traumatic brain injury. Our
studies support the contribution of IL-1β in inducing BBB dysfunction and hyperpermeability
as demonstrated in our in vitro permeability studies, changes in ZO-1 junctional localization,
Fig 9. Melatonin pretreatment attenuates TBI-induced BBB hyperpermeability studied by Evans blue dye
extravasation method (Panel A). Pictorial representation of the brain tissue from various groups is shown in
Panel 9B. Sham injury group was used as the baseline for all comparisons. Melatonin (10 μg/gram body
weight of the animal) pretreatment significantly attenuated TBI-induced Evans blue leakage into the
extravascular tissue space (p<0.05). Animals were divided into sham (n = 6), vehicle + sham (n = 6), vehicle
+ TBI (n = 5) and melatonin + TBI (n = 6). Data are expressed as ng/brain cortex ± SEM. ‘*’ indicates
statistical significance. ‘a’ indicates significant increase compared to the sham injury/vehicle + sham injury
group and ‘b’ indicates significant decrease compared to the vehicle + TBI group.
doi:10.1371/journal.pone.0154427.g009
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and f-actin stress fiber formation. Although, IL-1β treatment induced ZO-1 junctional disrup-
tion and BBB hyperpermeability, no change in the total ZO-1 protein or gene expression was
observed. These studies indicate a possibility that IL-1β treatment-induced alterations in the
BBB may not be due to changes at the gene or protein level but could be due to displacement of
ZO-1 from the tight junctions thus detaching itself from the transmembrane tight junction as
well as the actin cytoskeleton. Cytoskeletal changes in the form of increased actin stress fibers,
observed in our studies following IL-1β treatment parallel the alterations in monolayer perme-
ability and barrier dysfunctions. Recent studies demonstrate that actin stress fiber formation is
not necessarily connected to increase in permeability, but might actually reflect a cellular
response to repair disrupted barrier function [23,24]. Our observation thus, suggest that the
barrier is undergoing repair process and the hyperpermeability observed may be reversible.
The involvement of other intermediate signaling pathways that are activated by mitogen acti-
vated protein kinases like c-Jun N-terminal kinases (JNK) and p38 as described previously, are
also possible [3,25].
IL-1β treatment induces MMP-9 activity in brain endothelial cells in vitro and one of the
mechanisms by which MMP-9 inhibitor 1 and melatonin pretreatment attenuates IL-1β-
induced MMP-9 activity may occur by direct binding of MMP-9 inhibitor 1 and melatonin to
MMP-9. However, these studies need to be explored further in order to understand how
MMP-9 inhibitors inhibit IL-1β-induced BBB hyperpermeability. As MMP-9 is indicated to
activate protein kinase C via extracellular signal-regulated kinases (ERK) in TBI [26], this can
be a potential mechanism that needs further studies.
Our cell culture studies employ commercially available primary cultures of microvascular
endothelial cells isolated from rat brain. They are then cultured continuously for the purpose
of the experiment upto 8–10 passages. Although they are most representative to the in vivo
experimental models, they suffer from various limitations like relative short life span, suscepti-
bility to contamination and may not also fully act like a tissue due to the complexity of the
media apart from the fact that there is considerable variation in population and between prepa-
rations. These finite cell lines also tend to differentiate over a period of time and the culture
tends to select for aberrant cells.
The present study employed pharmacological and endogenous MMP-9 inhibitors i.e.
MMP-9 inhibitor 1 and melatonin in order to test their effect on IL-1β treatment- induced
BBB dysfunction and hyperpermeability. Use of melatonin has great advantage as it can cross
the BBB due to its lipophilic nature and can act as a neuroprotectant [27]; apart from the fact
that is a relatively less expensive drug that is available over-the- counter with no known adverse
effects. Our results underline the need for future studies to explore the therapeutic advantages
of melatonin against BBB dysfunction and edema formation following TBI. Our studies, while
supporting the recent observation that melatonin is protective against brain edema and ele-
vated ICP in a rat weight drop model of TBI [28], further shows how it works in an acute set-
ting and also its potential mechanisms of action at the level of the tight junctions of the blood-
brain barrier.
Although these results support the role of melatonin in regulating BBB endothelial functions
via MMP-9 inhibition, we do not believe its contribution is only owing to its MMP-9 inhibitory
properties and there is a need to explore other possible mechanisms. Future studies should aim
to address the effect of melatonin on 1) tissue inhibitors of MMPs (TIMPs), 2) transcription fac-
tors responsible for MMP-9 expression such as nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) and activator protein (AP-1), as suggested by Grossetete et al (2009)
[11], 3) on various ERKMAPK and 4) phosphorylation status of the tight junctions.
In conclusion, the preset study demonstrates that melatonin has protective effects against
acute IL-1β-induced BBB dysfunction and hyperpermeability via MMP-9 inhibition and by
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preserving tight junction integrity in vitro. The protective effects of melatonin in an acute set-
ting in vitro parallel with its protective effects against TBI in a controlled cortical impact model
of TBI in vivo and provide great promise to early regulation of secondary injuries.
Supporting Information
S1 Fig. Immunoblot analysis of MMP-9 demonstrating an insignificant reduction in
MMP-9 protein following MMP-9 siRNA transfection in RBMECs compared with control
siRNA group. A. Representative bands from immunoblot analysis. B. Analysis of the data
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